The rapid development of equitably accessible vaccines is paramount in addressing emerging global health challenges. The safety and efficacy of vaccines hinge significantly on their ability to remain stable from manufacturing throughout the supply chain and up to administration. Furthermore, the release of vaccines requires sufficient understanding of the stability profile to allow for expiration dating. In the event of a public health crisis, the time to generate the necessary stability data and the need for rapid product release are in direct opposition. Developing manufacturing platforms with thermostable product formulations for rapid response is therefore key to meeting CEPI's 100 Days Mission goal. This Review aims to highlight the need for stability preparedness through developing thermostable vaccine platforms and exploring innovative stability monitoring strategies that leverage advanced technologies, predictive modelling, and adaptive methodologies. By doing so, we seek to enhance the efficiency and effectiveness of stability assessments, supporting rapid development, regulatory approval, and widespread, equal distribution of vaccines-especially in an outbreak scenario. Finally, enhanced thermostability will allow for simplification across the supply chain, which will reduce the financial burden of vaccination programmes and enhance equitable access.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11435764 | PMC |
| http://dx.doi.org/10.3390/vaccines12091000 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccine Intention, Uptake, and Hesitancy Among US Certified Food Producers: The National COVID-19 Organic Farmer Study.
Disaster Med Public Health Prep
December 2024
College of Population Health, University of New Mexico, Albuquerque, NM, USA.
Objective: To estimate COVID-19 vaccine intention, uptake, and hesitancy among essential workers.
Methods: A cross-sectional survey of USDA-certified organic producers. An electronic survey was used for data collection.
Left out in the cold - inequity in infectious disease control due to cold chain disparity.
Vaccine
December 2024
CSIRO, Health and Biosecurity, Australian Centre for Disease Preparedness, Geelong, Victoria, Australia. Electronic address:
Vaccines and diagnostic tools stand out as among the most influential advancements in public health, credited with averting an estimated 6 million deaths annually and substantially alleviating the burden of infectious disease. Despite this progress, the global imperative to prevent, detect, and combat infectious disease persists. Regrettably, hundreds of thousands of lives are still lost due to inadequate access to vaccines and diagnostics.
View Article and Find Full Text PDFSerotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis.
Lancet Infect Dis
December 2024
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Article Synopsis
- The text discusses the impact of pneumococcal conjugate vaccines (PCVs), specifically PCV10 and PCV13, on invasive pneumococcal disease (IPD) globally, highlighting how these vaccines have reduced the prevalence of disease caused by vaccine-type serotypes after extensive use.
- It describes the methodology of data collection from various surveillance sites, which aimed to evaluate IPD cases that occurred five years after the vaccines were implemented, focusing on different age groups for analysis.
- Findings indicate significant differences in serotype distribution between PCV10 and PCV13 sites; notably, certain serotypes, such as 19A and serotype 3, were prevalent in specific age groups, signaling ongoing challenges in controlling
Developing a universal multi-epitope protein vaccine candidate for enhanced borna virus pandemic preparedness.
Front Immunol
December 2024
School of Basic Medicine, Guangzhou Medical University, Guangzhou, China.
Introduction: Borna disease virus 1 (BoDV-1) is an emerging zoonotic RNA virus that can cause severe acute encephalitis with high mortality. Currently, there are no effective countermeasures, and the potential risk of a future outbreak requires urgent attention. To address this challenge, the complete genome sequence of BoDV-1 was utilized, and immunoinformatics was applied to identify antigenic peptides suitable for vaccine development.
View Article and Find Full Text PDFAudit of preparedness of selected military hospital in the face of biological threats: action research study.
Int J Emerg Med
December 2024
Nursing Care Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Introduction: In today's societies, the threats caused by chemical, biological, radiological and nuclear accidents, whether accidental or intentional, have become a great concern. Acquiring knowledge about how to respond to the management of these incidents and the complications caused by them in order to preserve societies and ensure stability is essential. Due to the fact that hospitals play an important role in dealing with the victims of biological threats, this study was conducted with the aim of auditing the preparedness of selected military Hospital in facing biological threats in 2023-2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!